Literature DB >> 19816234

Eosinophilic inflammation in the middle ear induces deterioration of bone-conduction hearing level in patients with eosinophilic otitis media.

Yukiko Iino1, Hajime Usubuchi, Kozue Kodama, Hiromi Kanazawa, Katsumi Takizawa, Takeharu Kanazawa, Yasushi Ohta.   

Abstract

OBJECTIVE: Eosinophilic otitis media (EOM) is characterized by the extensive accumulation of eosinophils in the middle ear mucosa and middle ear effusion and is usually associated with bronchial asthma. Eosinophilic otitis media patients show gradual or sudden deterioration of hearing. In our previous study, we reported that high-tone loss was more frequently found and more severe in EOM patients than in control patients with chronic otitis media. These findings suggest that not only bacterial infection but also eosinophilic inflammation in the middle ear may damage the inner ear. The present study was performed to determine whether eosinophilic inflammation is indeed related to deterioration of bone-conduction hearing level (BCHL). PATIENTS: Fifty-five ears of 28 patients with EOM associated with bronchial asthma were included in this study. Middle ear effusion (MEE) samples were collected from all the patients, and the concentrations of eosinophilic cationic protein (ECP) and immunoglobulin E (IgE) were measured by fluorescence enzyme immunoassay. The BCHLs at 2 and 4 kHz for the worse-hearing ear of each patient were correlated with the concentrations of ECP and IgE.
RESULTS: The concentration of IgE in MEE significantly and positively correlated with BCHL at 2 and 4 kHz. The ears with a higher concentration of ECP in MEE also tended to show deterioration of BCHL at 4 kHz. Other clinical risk factors for BCHL deterioration were male sex, long duration of EOM, association with bacterial infection, severe inflammatory changes of the middle ear mucosa, and high serum IgE concentration.
CONCLUSION: Eosinophilic-inflammation-related substances such as ECP and IgE are closely related to the deterioration of BCHL at high frequencies. Particularly, IgE concentration in MEE is a good indicator of BCHL elevation. We should always pay attention to the hearing acuity of EOM patients with the risk factors.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19816234     DOI: 10.1097/MAO.0b013e3181bc3781

Source DB:  PubMed          Journal:  Otol Neurotol        ISSN: 1531-7129            Impact factor:   2.311


  7 in total

Review 1.  Is there an association between otitis media and nasal polyposis?

Authors:  Cécile Parietti-Winkler; Roger Jankowski
Journal:  Curr Allergy Asthma Rep       Date:  2011-12       Impact factor: 4.806

2.  Eosinophilic Otitis Media: Modern Aspects of Pathogenesis, Clinical Features, Diagnosis and Treatment.

Authors:  Elena Shevchik; Valery Svistushkin; Galina Nikiforova; Anna Zolotova
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2020-06-18

3.  Cytokine profile of nasal and middle ear polyps in a patient with Woakes' syndrome and eosinophilic otitis media.

Authors:  Marie De Loof; Els De Leenheer; Gabriële Holtappels; Claus Bachert
Journal:  BMJ Case Rep       Date:  2016-05-03

Review 4.  New Insights into Eosinophilic Otitis Media.

Authors:  Hiromi Kanazawa; Naohiro Yoshida; Yukiko Iino
Journal:  Curr Allergy Asthma Rep       Date:  2015-12       Impact factor: 4.806

Review 5.  Otitis media with effusion and atopy: is there a causal relationship?

Authors:  Mario E Zernotti; Ruby Pawankar; Ignacio Ansotegui; Hector Badellino; Juan Sebastian Croce; Elham Hossny; Motohiro Ebisawa; Nelson Rosario; Mario Sanchez Borges; Yuan Zhang; Luo Zhang
Journal:  World Allergy Organ J       Date:  2017-11-14       Impact factor: 4.084

Review 6.  Inner ear disturbances related to middle ear inflammation.

Authors:  Michihiko Sone
Journal:  Nagoya J Med Sci       Date:  2017-02       Impact factor: 1.131

Review 7.  Eosinophilic otitis media: CT and MRI findings and literature review.

Authors:  Won Jung Chung; Jeong Hyun Lee; Hyun Kyung Lim; Tae Hyun Yoon; Kyung Ja Cho; Jung Hwan Baek
Journal:  Korean J Radiol       Date:  2012-04-17       Impact factor: 3.500

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.